Roche Pharmaceutical Development and Sales Overview

Ocrevus Global sales CHFbn CER growth +17% Regional sales 4.9 4.2 3.5 2.8 2.1 1.4 0.7 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 4,427m • • US: Moving into earlier lines displacing orals; #1 in US for both total share and NTB EU: Moving into earlier lines displacing orals; #1 in EU5 for both total share and NTB CER-Constant Exchange Rates US CER growth +13% Europe +25% International +37% Roche 151

View entire presentation